NASDAQ:OM

Outset Medical Competitors

$54.50
-0.05 (-0.09 %)
(As of 04/14/2021 04:30 PM ET)
Add
Compare
Today's Range
$53.92
Now: $54.50
$56.52
50-Day Range
$46.94
MA: $51.67
$58.33
52-Week Range
$42.50
Now: $54.50
$66.96
Volume293,161 shs
Average Volume382,559 shs
Market Capitalization$2.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Outset Medical (NASDAQ:OM) Vs. LIVN, CNMD, INMD, BLFS, NTUS, and AXGN

Should you be buying OM stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Outset Medical, including LivaNova (LIVN), CONMED (CNMD), InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), and AxoGen (AXGN).

Outset Medical (NASDAQ:OM) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Valuation and Earnings

This table compares Outset Medical and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.42

Outset Medical has higher earnings, but lower revenue than LivaNova.

Profitability

This table compares Outset Medical and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
LivaNova-21.88%5.55%3.07%

Insider & Institutional Ownership

84.6% of Outset Medical shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Outset Medical and LivaNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
LivaNova04202.33

Outset Medical presently has a consensus target price of $56.50, indicating a potential upside of 3.67%. LivaNova has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts plainly believe Outset Medical is more favorable than LivaNova.

Summary

LivaNova beats Outset Medical on 5 of the 9 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Valuation & Earnings

This table compares Outset Medical and CONMED's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
CONMED$955.10 million3.95$28.62 million$2.6449.41

CONMED has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
CONMED0.04%9.48%3.75%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Outset Medical and CONMED, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
CONMED02402.67

Outset Medical presently has a consensus target price of $56.50, indicating a potential upside of 3.67%. CONMED has a consensus target price of $104.60, indicating a potential downside of 19.82%. Given Outset Medical's higher possible upside, equities research analysts clearly believe Outset Medical is more favorable than CONMED.

Insider and Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CONMED beats Outset Medical on 6 of the 8 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Valuation and Earnings

This table compares Outset Medical and InMode's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
InMode$156.36 million17.08$61.15 million$1.6052.21

InMode has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
InMode32.57%28.56%24.14%

Analyst Recommendations

This is a breakdown of current recommendations for Outset Medical and InMode, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
InMode00403.00

Outset Medical currently has a consensus target price of $56.50, indicating a potential upside of 3.67%. InMode has a consensus target price of $71.50, indicating a potential downside of 14.40%. Given Outset Medical's higher possible upside, research analysts plainly believe Outset Medical is more favorable than InMode.

Insider & Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

InMode beats Outset Medical on 5 of the 7 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Insider & Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Outset Medical and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
BioLife Solutions12.67%0.53%0.43%

Valuation and Earnings

This table compares Outset Medical and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
BioLife Solutions$27.37 million40.99$-1,660,000.00$0.08419.88

Outset Medical has higher earnings, but lower revenue than BioLife Solutions.

Analyst Recommendations

This is a breakdown of current recommendations for Outset Medical and BioLife Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
BioLife Solutions01902.90

Outset Medical currently has a consensus target price of $56.50, indicating a potential upside of 3.67%. BioLife Solutions has a consensus target price of $46.6667, indicating a potential upside of 38.93%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Outset Medical.

Summary

BioLife Solutions beats Outset Medical on 8 of the 9 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Natus Medical and Outset Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Outset Medical03402.57

Outset Medical has a consensus price target of $56.50, indicating a potential upside of 3.67%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts plainly believe Outset Medical is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Outset MedicalN/AN/AN/A

Valuation & Earnings

This table compares Natus Medical and Outset Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.96$-15,670,000.00$1.2423.09
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than Natus Medical.

Summary

Natus Medical beats Outset Medical on 5 of the 9 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Insider & Institutional Ownership

78.4% of AxoGen shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 6.9% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares AxoGen and Outset Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.42$-29,140,000.00($0.68)-28.56
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than AxoGen.

Profitability

This table compares AxoGen and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Outset MedicalN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AxoGen and Outset Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Outset Medical03402.57

AxoGen presently has a consensus target price of $23.75, indicating a potential upside of 22.30%. Outset Medical has a consensus target price of $56.50, indicating a potential upside of 3.67%. Given AxoGen's stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than Outset Medical.

Summary

Outset Medical beats AxoGen on 5 of the 9 factors compared between the two stocks.


Outset Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LivaNova logo
LIVN
LivaNova
1.5$81.37-0.8%$3.99 billion$1.08 billion-18.92Analyst Report
News Coverage
CNMD
CONMED
1.6$130.45-1.1%$3.82 billion$955.10 million-3,261.25
InMode logo
INMD
InMode
1.5$83.53-0.4%$2.68 billion$156.36 million60.09Analyst Downgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.59-3.2%$1.16 billion$27.37 million-46.01Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.63-4.5%$926.45 million$495.52 million-52.05
AxoGen logo
AXGN
AxoGen
1.5$19.42-1.2%$801.17 million$106.71 million-30.83News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$29.13-0.7%$792.09 million$23.60 million-20.81Increase in Short Interest
Gap Down
ViewRay logo
VRAY
ViewRay
1.3$4.43-2.9%$691.44 million$87.78 million-4.98
Cutera logo
CUTR
Cutera
1.3$30.78-1.6%$556.07 million$181.71 million-17.01
Zynex logo
ZYXI
Zynex
1.8$15.19-1.1%$523.87 million$45.47 million46.03
Edap Tms logo
EDAP
Edap Tms
1.3$9.06-1.4%$267.82 million$50.23 million-151.00Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24-1.8%$195.07 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.21-2.6%$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$17.98-0.1%$117.78 million$85.69 million16.96
IRIDEX logo
IRIX
IRIDEX
0.9$7.41-1.2%$113.61 million$43.45 million-13.47
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22-2.5%$94.87 millionN/A-1.61Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.28-3.5%$94.85 million$10,000.00-1.24Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.82-1.1%$89.20 million$2.39 million-2.30Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56-0.7%$40.28 million$1.50 million-1.00Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33-1.7%$31.63 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01-0.3%$31.03 million$6.57 million-0.01
STRR
Star Equity
0.1$3.19-3.4%$16.24 million$114.18 million-1.02
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.